Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study was written by Lim, Sean H.;Stuart, Beth;Joseph-Pietras, Debora;Johnson, Marina;Campbell, Nicola;Kelly, Adam;Jeffrey, Danielle;Turaj, Anna H.;Rolfvondenbaumen, Kate;Galloway, Celine;Wynn, Thomas;Coleman, Adam R.;Ward, Benjamin;Long, Karen;Coleman, Helen;Mundy, Carina;Bates, Andrew T.;Ayres, Diana;Lown, Robert;Falconer, Janlyn;Brake, Oliver;Batchelor, James;Willimott, Victoria;Bowzyk Al-Naeeb, Anna;Robinson, Lisa;O’Callaghan, Ann;Collins, Graham P.;Menne, Tobias;Faust, Saul N.;Fox, Christopher P.;Ahearne, Matthew;Johnson, Peter W. M.;Davies, Andrew J.;Goldblatt, David. And the article was included in Nature Cancer in 2022.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:
Patients with hematol. malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. We present the PROSECO prospective observational study (NCT04858568) on 457 patients with lymphoma that received 2 or 3 COVID-19 vaccine doses. We show undetectable humoral responses following 2 vaccine doses in 52% of patients undergoing active anticancer treatment. Moreover, 60% of patients on anti-CD20 therapy had undetectable antibodies following full vaccination within 12 mo of receiving their anticancer therapy. However, 70% of individuals with indolent B-cell lymphoma displayed improved antibody responses following booster vaccination. Notably, 63% of all patients displayed antigen-specific T-cell responses, which increased after a 3rd dose irresp. of their cancer treatment status. Our results emphasize the urgency of careful monitoring of COVID-19-specific immune responses to guide vaccination schemes in these vulnerable populations. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Synthetic Route of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem